Identification of novel germline polymorphisms governing capecitabine sensitivity

Peter H. O'Donnell, Amy L. Stark, Eric R. Gamazon, Heather E. Wheeler, Bridget E. McIlwee, Lidija Gorsic, Hae Kyung Im, R. Stephanie Huang, Nancy J. Cox, M. Eileen Dolan

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


BACKGROUND: Capecitabine, an oral 5-fluorouracil (5-FU) prodrug, is widely used in the treatment of breast, colorectal, and gastric cancers. To guide the selection of patients with potentially the greatest benefit of experiencing antitumor efficacy, or, alternatively, of developing toxicities, identifying genomic predictors of capecitabine sensitivity could permit its more informed use. METHODS: The objective of this study was to perform capecitabine sensitivity genome-wide association studies (GWAS) using 503 well genotyped human cell lines from individuals representing multiple different world populations. A meta-analysis that included all ethnic populations then enabled the identification of novel germline determinants (single nucleotide polymorphisms [SNPs]) of capecitabine susceptibility. RESULTS: First, an intrapopulation GWAS of Caucasian individuals identified reference SNP 4702484 (rs4702484) (within adenylate cyclase 2 [ADCY2]) at a level reaching genome-wide significance (P = 5.2 × 10 -8). This SNP is located upstream of the 5 methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) gene, and it is known that the enzyme for MTRR is involved in the methionine-folate biosynthesis and metabolism pathway, which is the primary target of 5-FU-related compounds, although the authors were unable to identify a direct relation between rs4702484 and MTRR expression in a tested subset of cells. In the meta-analysis, 4 SNPs comprised the top hits, which, again, included rs4702484 and 3 additional SNPs (rs8101143, rs576523, and rs361433) that approached genome-wide significance (P values from 1.9 × 10 -7 to 8.8 × 10 -7). The meta-analysis also identified 1 missense variant (rs11722476; serine to asparagine) within switch/sucrose nonfermentable-related, matrix-associated, actin-dependent regulator of chromatin (SMARCAD1), a novel gene for association with capecitabine/5-FU susceptibility. CONCLUSIONS: Toward the goal of individualizing cancer chemotherapy, the current study identified novel SNPs and genes associated with capecitabine sensitivity that are potentially informative and testable in any patient regardless of ethnicity. Cancer 2011. © 2011 American Cancer Society. To guide the selection of patients potentially at greatest benefit of experiencing antitumor efficacy from capecitabine, or, alternatively, of developing capecitabine toxicities, the authors identify several novel germline predictors of capecitabine sensitivity using a genome-wide and meta-analysis approach.

Original languageEnglish (US)
Pages (from-to)4063-4073
Number of pages11
Issue number16
StatePublished - Aug 15 2012


  • capecitabine
  • genome-wide
  • meta-analysis
  • pharmacogenomics
  • susceptibility

Fingerprint Dive into the research topics of 'Identification of novel germline polymorphisms governing capecitabine sensitivity'. Together they form a unique fingerprint.

Cite this